EA201690445A1 - Лечение рака - Google Patents

Лечение рака

Info

Publication number
EA201690445A1
EA201690445A1 EA201690445A EA201690445A EA201690445A1 EA 201690445 A1 EA201690445 A1 EA 201690445A1 EA 201690445 A EA201690445 A EA 201690445A EA 201690445 A EA201690445 A EA 201690445A EA 201690445 A1 EA201690445 A1 EA 201690445A1
Authority
EA
Eurasian Patent Office
Prior art keywords
cancer treatment
subject
cancer
treatment
trichostatin
Prior art date
Application number
EA201690445A
Other languages
English (en)
Other versions
EA037667B1 (ru
Inventor
Михаэль Х. Полимеропулос
Луис Уилльям Лайкамил
Кристиан Лэйвдэн
Original Assignee
Ванда Фармасьютикалз Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ванда Фармасьютикалз Инк. filed Critical Ванда Фармасьютикалз Инк.
Publication of EA201690445A1 publication Critical patent/EA201690445A1/ru
Publication of EA037667B1 publication Critical patent/EA037667B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Abstract

Изобретение в основном относится к лечению рака. Один вариант осуществления изобретения представляет способ лечения рака у субъекта, включающий введение субъекту эффективного количества трихостатина A (TSA).
EA201690445A 2013-08-22 2014-08-22 Лечение рака EA037667B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361869039P 2013-08-22 2013-08-22
PCT/US2014/052209 WO2015027121A2 (en) 2013-08-22 2014-08-22 Cancer treatment

Publications (2)

Publication Number Publication Date
EA201690445A1 true EA201690445A1 (ru) 2016-06-30
EA037667B1 EA037667B1 (ru) 2021-04-28

Family

ID=51794948

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201690445A EA037667B1 (ru) 2013-08-22 2014-08-22 Лечение рака

Country Status (12)

Country Link
US (5) US20160199323A1 (ru)
EP (2) EP3036007B1 (ru)
JP (4) JP2016528297A (ru)
KR (5) KR20170126018A (ru)
CN (2) CN105579101A (ru)
AU (4) AU2014308700A1 (ru)
CA (1) CA2921036A1 (ru)
CL (1) CL2016000397A1 (ru)
EA (1) EA037667B1 (ru)
ES (1) ES2755983T3 (ru)
MX (1) MX2016002307A (ru)
WO (1) WO2015027121A2 (ru)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20170126018A (ko) * 2013-08-22 2017-11-15 반다 파마슈티칼즈, 인코퍼레이티드. 암 치료
WO2021016203A1 (en) * 2019-07-19 2021-01-28 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Pdlim2 as a biomarker for cancer and as an anti-cancer treatment target
WO2023168201A1 (en) * 2022-03-01 2023-09-07 Vanda Pharmaceuticals Inc. Trichostatin a (tsa) sensitivity in the treatment of tumors

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4218478A (en) * 1979-01-05 1980-08-19 Ruiko Oiwa Trichostatin as an antiprotozoal agent
CA1265431A (en) 1985-01-08 1990-02-06 Roderick John Macdonald Electrode device for flare stack ignitor
JPS61176523A (ja) * 1985-01-30 1986-08-08 Teruhiko Beppu 制癌剤
WO2002060430A1 (en) * 2001-02-01 2002-08-08 Cornell Research Foundation, Inc. Use of retinoids plus histone deacetylase inhibitors to inhibit the growth of solid tumors
ES2397079T3 (es) * 2003-06-27 2013-03-04 Astellas Pharma Inc. Agente terapéutico para sarcoma de tejidos blandos
CA3142853A1 (en) 2004-05-21 2005-12-08 The Board Of Trustees Of The University Of Arkansas Use of gene expression profiling to predict survival in cancer patient
WO2007067516A2 (en) * 2005-12-06 2007-06-14 Duke University Multiple myeloma
EP2023912A2 (en) 2006-05-26 2009-02-18 Celgene Corporation Methods and compositions using immunomodulatory compounds in combination therapy
CA2574531C (en) * 2007-01-19 2016-10-25 The University Of British Columbia Hat acetylation promoters and uses of compositions thereof in promoting immunogenicity
US20120107304A1 (en) 2010-04-27 2012-05-03 Boehringer Ingelheim International Gmbh Combination therapy in treatment of oncological and fibrotic diseases
CN110354132A (zh) * 2012-06-04 2019-10-22 药品循环有限责任公司 布鲁顿酪氨酸激酶抑制剂的晶形
KR20170126018A (ko) * 2013-08-22 2017-11-15 반다 파마슈티칼즈, 인코퍼레이티드. 암 치료
MX2016002308A (es) 2013-08-22 2016-06-15 Vanda Pharmaceuticals Inc Tratamiento del mieloma multiple.

Also Published As

Publication number Publication date
JP2019167351A (ja) 2019-10-03
AU2021261882A1 (en) 2021-12-02
KR20210013343A (ko) 2021-02-03
US10265282B2 (en) 2019-04-23
US20180256522A1 (en) 2018-09-13
KR102315528B1 (ko) 2021-10-21
CN110585184A (zh) 2019-12-20
US11078289B2 (en) 2021-08-03
CN105579101A (zh) 2016-05-11
US20210324093A1 (en) 2021-10-21
KR20160033779A (ko) 2016-03-28
JP2023088996A (ja) 2023-06-27
EP3036007B1 (en) 2019-10-09
WO2015027121A3 (en) 2015-05-14
US20230257471A1 (en) 2023-08-17
KR20210127821A (ko) 2021-10-22
US11667718B2 (en) 2023-06-06
WO2015027121A2 (en) 2015-02-26
AU2021261882B2 (en) 2022-04-14
US20160199323A1 (en) 2016-07-14
ES2755983T3 (es) 2020-04-24
EP3036007A2 (en) 2016-06-29
JP2021105005A (ja) 2021-07-26
CA2921036A1 (en) 2015-02-26
KR20230047203A (ko) 2023-04-06
US20190211107A1 (en) 2019-07-11
AU2014308700A1 (en) 2016-02-25
MX2016002307A (es) 2016-06-15
JP2016528297A (ja) 2016-09-15
EP3616754A1 (en) 2020-03-04
KR20170126018A (ko) 2017-11-15
NZ716668A (en) 2021-02-26
AU2022202183B2 (en) 2023-09-28
EA037667B1 (ru) 2021-04-28
AU2019261718A1 (en) 2019-11-28
CL2016000397A1 (es) 2017-03-17
AU2022202183A1 (en) 2022-04-21

Similar Documents

Publication Publication Date Title
PH12015502075B1 (en) Treatment of cataplexy
EA201890411A1 (ru) Терапевтически активные соединения и способы их применения
EA201591674A1 (ru) Противораковые вакцины и способы лечения с их применением
ES2765949T8 (es) Terapia que involucra anticuerpos contra la claudina 18.2 para el tratamiento del cáncer
PH12016500511A1 (en) Selective grp94 inhibitors and uses thereof
BR112015007494A2 (pt) aparelho para tratamento dentário.
MX2016002826A (es) Anticuerpos anti-b7-h1 para tratar tumores.
EA201590987A1 (ru) Соединения и способы их применения
DK2958945T3 (da) Kombinationsterapi med antistoffer mod claudin 18.2 til behandling af cancer
MX2015010312A (es) Metodos para tratamiento del melanoma.
EA201400178A1 (ru) Лечение рака молочной железы
MX2015011606A (es) Metodo para tratar cancer y prevenir resistencia a farmacos contra cancer.
MX2015011783A (es) Metodos para tratar tumores solidos pediatricos.
EA201690513A1 (ru) Комбинация ингибитора mek и ингибитора erk для применения в лечении гиперпролиферативных заболеваний
EP2944323A4 (en) MEANS FOR THE TREATMENT OF TUMORS, USE AND METHOD THEREFOR
MX2015014590A (es) Tratamiento de cancer con dihidropirazino-pirazinas.
BR112019001398A2 (pt) métodos para tratamento de câncer de próstata
EA201690039A1 (ru) Ингибиторы rorc2 и способы их применения
EA201790312A1 (ru) Комбинации лекарственных средств для лечения множественной миеломы
EA201692534A1 (ru) Способы лечения гипотонии
EA201591507A1 (ru) Лечение рассеянного склероза лахинимодом
SG11201507222WA (en) Non-woven face mask and corresponding cosmetic treatment method.
BR112016012248A2 (pt) método de tratamento de nefropatia
EA201690446A1 (ru) Лечение множественной миеломы
EA201491581A1 (ru) Везикулярные композиции